Patents by Inventor Steven R. Fuhrmann

Steven R. Fuhrmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ISOLATED POLYPEPTIDE OF THE TOXIN A AND TOXIN B PROTEINS OF C. DIFFICILE AND USES THEREOF
    Publication number: 20230173052
    Abstract: This present invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides comprising the receptor binding domains of C. difficile toxin A and toxin B as set forth in the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4. The C-TAB.G5 and C-TAB.G5.1 isolated polypeptides may be used to neutralize toxic effects of C. difficile toxin A and/or toxin B.
    Type: Application
    Filed: September 9, 2022
    Publication date: June 8, 2023
    Applicants: VALNEVA AUSTRIA GMBH, VALNEVA USA, INC.
    Inventors: Larry R. Ellingsworth, David Flyer, Jing-Hui Tian, Steven R. Fuhrmann, Stefanie Kluepfel-Stahl, Gregory M. Glenn, Kerstin Westritschnig
  • Isolated polypeptide of the toxin A and toxin B proteins of and uses thereof
    Patent number: 11478540
    Abstract: This present invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides comprising the receptor binding domains of C. difficile toxin A and toxin B as set forth in the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4. The C-TAB.G5 and C-TAB.G5.1 isolated polypeptides may be used to neutralize toxic effects of C. difficile toxin A and/or toxin B.
    Type: Grant
    Filed: August 19, 2021
    Date of Patent: October 25, 2022
    Assignees: Valneva Austria GmbH, Valneva USA, Inc.
    Inventors: Larry R. Ellingsworth, David Flyer, Jing-Hui Tian, Steven R. Fuhrmann, Stefanie Kluepfel-Stahl, Gregory M. Glenn, Kerstin Westritschnig
  • Isolated polypeptide of the toxin A and toxin B proteins of and uses thereof
    Patent number: 11357844
    Abstract: This present invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides comprising the receptor binding domains of C. difficile toxin A and toxin B as set forth in the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4. The C-TAB.G5 and C-TAB.G5.1 isolated polypeptides may be used to neutralize toxic effects of C. difficile toxin A and/or toxin B.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: June 14, 2022
    Assignees: Valneva Austria GmbH, Valneva USA, Inc.
    Inventors: Larry R. Ellingsworth, David Flyer, Jing-Hui Tian, Steven R. Fuhrmann, Stefanie Kluepfel-Stahl, Gregory M. Glenn, Kerstin Westritschnig
  • ISOLATED POLYPEPTIDE OF THE TOXIN A AND TOXIN B PROTEINS OF C. DIFFICILE AND USES THEREOF
    Publication number: 20210393761
    Abstract: This present invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides comprising the receptor binding domains of C. difficile toxin A and toxin B as set forth in the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4. The C-TAB.G5 and C-TAB.G5.1 isolated polypeptides may be used to neutralize toxic effects of C. difficile toxin A and/or toxin B.
    Type: Application
    Filed: August 19, 2021
    Publication date: December 23, 2021
    Inventors: Larry R. Ellingsworth, David Flyer, Jing-Hui Tian, Steven R. Fuhrmann, Stefanie Kluepfel-Stahl, Gregory M. Glenn, Kerstin Westritschnig
  • ISOLATED POLYPEPTIDE OF THE TOXIN A AND TOXIN B PROTEINS OF C. DIFFICILE AND USES THEREOF
    Publication number: 20210121554
    Abstract: This present invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides comprising the receptor binding domains of C. difficile toxin A and toxin B as set forth in the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4. The C-TAB.G5 and C-TAB.G5.1 isolated polypeptides may be used to neutralize toxic effects of C. difficile toxin A and/or toxin B.
    Type: Application
    Filed: October 2, 2020
    Publication date: April 29, 2021
    Applicants: Valneva Austria GmbH, Valneva USA, Inc.
    Inventors: Larry R. Ellingsworth, David Flyer, Jing-Hui Tian, Steven R. Fuhrmann, Stefanie Kluepfel-Stahl, Gregory M. Glenn, Kerstin Westritschnig
  • Isolated polypeptide of the toxin A and toxin B proteins of and uses thereof
    Patent number: 10821166
    Abstract: This present invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides comprising the receptor binding domains of C. difficile toxin A and toxin B as set forth in the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4. The C-TAB.G5 and C-TAB.G5.1 isolated polypeptides may be used to neutralize toxic effects of C. difficile toxin A and/or toxin B.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: November 3, 2020
    Assignees: Valneva Austria GmbH, Valneva USA, Inc.
    Inventors: Larry R. Ellingsworth, David Flyer, Jing-Hui Tian, Steven R. Fuhrmann, Stefanie Kluepfel-Stahl, Gregory M. Glenn, Kerstin Westritschnig
  • ISOLATED POLYPEPTIDE OF THE TOXIN A AND TOXIN B PROTEINS OF C. DIFFICILE AND USES THEREOF
    Publication number: 20190290747
    Abstract: This present invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides comprising the receptor binding domains of C. difficile toxin A and toxin B as set forth in the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4. The C-TAB.G5 and C-TAB.G5.1 isolated polypeptides may be used to neutralize toxic effects of C. difficile toxin A and/or toxin B.
    Type: Application
    Filed: March 7, 2019
    Publication date: September 26, 2019
    Applicant: Valneva Austria GmbH
    Inventors: Larry R. Ellingsworth, David Flyer, Jing-Hui Tian, Steven R. Fuhrmann, Stefanie Kluepfel-Stahl, Gregory M. Glenn, Kerstin Westritschnig
  • Isolated polypeptide of the toxin A and toxin B proteins of and uses thereof
    Patent number: 10357557
    Abstract: This present invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides comprising the receptor binding domains of C. difficile toxin A and toxin B as set forth in the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4. The C-TAB.G5 and C-TAB.G5.1 isolated polypeptides may be used to neutralize toxic effects of C. difficile toxin A and/or toxin B.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: July 23, 2019
    Assignees: Valneva Austria GmbH, Valneva USA, Inc.
    Inventors: Larry R. Ellingsworth, David Flyer, Jing-Hui Tian, Steven R. Fuhrmann, Stefanie Kluepfel-Stahl, Gregory M. Glenn, Kerstin Westritschnig
  • ISOLATED POLYPEPTIDE OF THE TOXIN A AND TOXIN B PROTEINS OF C. DIFFICILE AND USES THEREOF
    Publication number: 20170239340
    Abstract: This present invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides comprising the receptor binding domains of C. difficile toxin A and toxin B as set forth in the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4. The C-TAB.G5 and C-TAB.G5.1 isolated polypeptides may be used to neutralize toxic effects of C. difficile toxin A and/or toxin B.
    Type: Application
    Filed: February 1, 2017
    Publication date: August 24, 2017
    Applicants: Valneva Austria GmbH, Intercell USA, Inc.
    Inventors: LARRY R. ELLINGSWORTH, David Flyer, Jing-Hui Tian, Steven R. Fuhrmann, Stefanie Kluepfel-Stahl, Gregory M. Glenn, Kerstin Westritschnig
  • Isolated polypeptide of the toxin A and toxin B proteins of and uses thereof
    Patent number: 9598472
    Abstract: This present invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides comprising the receptor binding domains of C. difficile toxin A and toxin B as set forth in the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4. The C-TAB.G5 and C-TAB.G5.1 isolated polypeptides may be used to neutralize toxic effects of C. difficile toxin A and/or toxin B.
    Type: Grant
    Filed: September 5, 2011
    Date of Patent: March 21, 2017
    Assignees: Valneva Austria GmbH, Intercell USA, Inc.
    Inventors: Larry R. Ellingsworth, David Flyer, Jing-Hui Tian, Steven R. Fuhrmann, Stefanie Kluepfel-Stahl, Gregory M. Glenn, Kerstin Westritschnig
  • ISOLATED POLYPEPTIDE OF THE TOXIN A AND TOXIN B PROTEINS OF C. DIFFICILE AND USES THEREOF
    Publication number: 20150056238
    Abstract: This present invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides comprising the receptor binding domains of C. difficile toxin A and toxin B as set forth in the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4. The C-TAB.G5 and C-TAB.G5.1 isolated polypeptides may be used to neutralize toxic effects of C. difficile toxin A and/or toxin B.
    Type: Application
    Filed: September 5, 2011
    Publication date: February 26, 2015
    Applicants: Intercell USA, Inc., Valneva Austria GmbH
    Inventors: Larry R. Ellingsworth, David Flyer, Jing-Hui Tian, Steven R. Fuhrmann, Stefanie Kluepfel-Stahl, Gregory M. Glenn, Kerstin Westritschnig